Bulletin
Investor Alert

New York Markets After Hours

Arbutus Biopharma Corp.

NAS: ABUS

GO
/marketstate/country/us

After Hours

/zigman2/quotes/203237619/composite

$

3.08

Change

-0.0001 -0.0032%

Volume

Volume 11,618

Sep 25, 2020, 4:21 p.m.

Real time quotes

/zigman2/quotes/203237619/composite

Today's close

$ 2.92

$ 3.08

Change

+0.16 +5.48%

Day low

Day high

$2.93

$3.14

Open
Open: 2.93

52 week low

52 week high

$0.82

$9.02

Open

Market cap

$242.10M

Average volume

11.46M

P/E ratio

N/A

Rev. per Employee

$74,313

EPS

-2.45

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/abus

MarketWatch News on ABUS

  1. Moderna Lost a Patent Case and the Stock Is Slipping

    3:31 p.m. July 24, 2020

    - Barron's Online

  2. Arbutus Biopharma upgraded to outperform from neutral at Wedbush

    7:32 a.m. May 19, 2020

    - Tomi Kilgore

  3. Arbutus Biopharma stock price target cut to $3 from $7 at B. Riley FBR

    8:09 a.m. Oct. 7, 2019

    - Tomi Kilgore

  4. Arbutus Biopharma upgraded to neutral from underperform at Wedbush, price target $5

    9:24 a.m. Oct. 15, 2018

    - Tonya Garcia

  5. Harry Boxer’s three drug stocks to watch

    10:26 a.m. July 19, 2018

    - Harry Boxer

  6. Harry Boxer’s four health-care stocks to watch

    12:54 p.m. July 12, 2018

    - Harry Boxer

  7. Arbutus Biopharma downgraded to neutral from outperform at Wedbush

    7:43 a.m. March 19, 2018

    - Tomi Kilgore

  8. 10 biotech stocks to buy at ‘silly’ cheap prices

    11:10 a.m. Jan. 16, 2016

    - Michael Brush

  9. Now that outbreak is over, whatever happened to Ebola stocks?

    4:07 p.m. Jan. 14, 2016

    - Wallace Witkowski

  10. Tekmira: With Its Ebola Drug Gone, Is It Worth the Risk?

    4:01 p.m. June 19, 2015

    - Barrons Blogs

  11. Tekmira halts enrollment on Ebola tests; shares fall

    12:50 p.m. June 19, 2015

    - Russ Britt

  12. Axovant IPO sparks talk of a biotech bubble

    2:38 p.m. June 12, 2015

    - Ciara Linnane

  13. Gilead Sciences: Does Hepatitis-B Failure Mean More M&A?

    12:03 p.m. May 27, 2015

    - Barrons Blogs

  14. Tekmira gets nod for more Ebola drug testing

    12:24 p.m. April 10, 2015

    - Russ Britt

  15. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/abus

Other News on ABUS

  1. Arbutus Biopharma (ABUS) Receives a Buy from B.Riley FBR

    5:08 a.m. Sept. 23, 2020

    - SmarterAnalyst

  2. Chardan Capital Reiterates a Buy Rating on Arbutus Biopharma (ABUS)

    12:25 p.m. Sept. 15, 2020

    - SmarterAnalyst

  3. NEE, NVAX among premarket gainers

    8:36 a.m. Sept. 15, 2020

    - Seeking Alpha

  4. Arbutus' AB-729 shows positive action in HBV study

    7:54 a.m. Sept. 15, 2020

    - Seeking Alpha

  5. Arbutus Biopharma (ABUS) Receives a Buy from Chardan Capital

    6:45 p.m. Aug. 28, 2020

    - SmarterAnalyst

  6. ABT, CLVS among premarket gainers

    8:21 a.m. Aug. 27, 2020

    - Seeking Alpha

  7. TSLA, MRNA among premarket gainers

    8:19 a.m. Aug. 12, 2020

    - Seeking Alpha

  8. 10-Q: ARBUTUS BIOPHARMA CORP

    4:27 p.m. Aug. 7, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  9. Loading more headlines...
/news/pressrelease/company/us/abus

Press Releases on ABUS

  1. Ebola Treatment Market Analysis and Global Research Report 2020 to 2026

    3:15 a.m. Aug. 28, 2020

    - Market Insight Reports

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.